• English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
August 26th - This week, central bank officials from around the world will gather in Jackson Hole, Wyoming, to discuss how to re-examine global inflation and the prospect of further increases in borrowing costs in the face of new inflationary threats. Spiros, an economist at Thin Ice Macro in Frankfurt, stated, "Global central banks are likely to adopt a cautious stance, viewing inflation as the risk they least want to see. You never know when the next supply shock will suddenly appear." Subadra Rajapa, head of US research at Societe Generale, noted that countries differ in their urgency regarding inflation, partly due to their varying degrees of sensitivity to energy cost fluctuations, which in turn depend on their import volumes. He pointed out that Europe and Japan are "more sensitive to the situation in the Middle East and oil prices." "We estimate that policy rates in the US and UK will remain tight," said Jarry Stern, chief European economist at Goldman Sachs. "Different starting points mean different pressures on countries to cope with the energy shock, giving the Fed and the Bank of England more time to observe how this shock evolves." Former Philadelphia Fed President Patrick Harker said, "The Iran war has changed the way people discuss issues and make policy choices, and there seems to be no end in sight." "This makes this years Jackson Hole symposium completely different because we are now in a typical supply shock environment, or more accurately, multiple supply shocks hitting the global economy simultaneously."On August 26, CanSino Biologics (06185.HK) issued an announcement on the Hong Kong Stock Exchange, noting the companys recent market developments regarding mRNA technology. The mRNA platform is one of the companys key technology platforms. The company is currently developing mRNA preventative vaccines and therapeutic biological products, as well as related delivery systems. In the therapeutic areas, the company is advancing research and development of mRNA vaccines for the treatment of glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of InVivoCAR-related therapies, all currently in early stages.The UKs CBI retail sales expectations index rose to -22 in August from -26, the highest level since March.The UKs CBI Retail Sales Expectations Index for August was -22, compared to -26 previously.The UK CBI retail sales balance for August was -48, compared to -26 in the previous month.

Phillips 66 Trademarks Mark Lashier will Succeed Greg Garland as CEO

Haiden Holmes

Apr 13, 2022 09:44

P2.png


Lashier, a chemical engineer who joined the firm three decades ago in the chemicals division, was named president and chief operating officer a year ago after leading Chevron Phillips Chemical Co, the company's joint venture with Chevron Corp (NYSE:CVX), since 2017.


Garland has considered refining as a mature company and has concentrated its efforts on expanding its energy infrastructure, chemicals, and establishing a presence in electric vehicle battery components. It spent around $150 million last year for a 16.5% share in Novonix Ltd, an Australian provider of lithium-ion battery materials.


Garland "built a market-leading diversified energy manufacturing and logistics organization while investing for the future and producing solid financial returns," according to Glen Tilton, lead independent director of Philips 66.


Although the Houston company's non-refining initiatives have generated great shareholder returns, its shares have lately underperformed bigger competitors that benefitted from increasing gasoline margins during pandemic lockdowns.


Lashier is expected to pursue Garland's diversification approach, which includes biofuels, hydrogen, and battery components. However, he must demonstrate that he can match competitors Marathon Petroleum Corp (NYSE:MPC) and Valero Energy (NYSE:VLO), which increased shareholder returns by selling off retail operations and diversifying into renewable diesel, analysts said.


Phillips 66 (NYSE:PSX) traded at $81.97 on Tuesday, up 13% year to date, compared to 34% year-to-year gains at Marathon and Valero and around 96% year-to-date gains at PBF Energy (NYSE:PBF).


"Lashier's task is to increase the company's value," Matthew Blair, an analyst at Tudor Pickering Holt & Co., said. "He will face inquiries regarding the company's non-refining businesses' value and what he can do to boost stock price performance and capitalize on the potential valuation."